Linzess Oral Capsule 145Mcg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Linzess: Oral capsule (145mcg)

Detailed Information
Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Visit Drug Summary Page
Drug Image file DrugItem_18054.JPG
Linzess 145mcg Capsule
Allergan USA, Inc.
Pill Identification: FL 145 

What is this Medicine?

LINACLOTIDE (lin a KLOE tide) is used to treat irritable bowel syndrome (IBS) with constipation as the main problem. It may also be used for relief of chronic constipation.

CVS Pharmacy Patient Statistics for Linzess: Oral capsule(145mcg)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information

Linzess 145mcg Capsule

NDC: 004561201
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Constipation, Irritable Bowel Syndrome

Storage Information
Store in a dry place
Store in original container
Protect from moisture
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Linzess 145mcg Capsule
Drug Image file DrugItem_18054.JPG
Allergan USA, Inc.
Pill Identification: FL 145 
Shape: capsule
Color: white
Ingredients
Close All Sections Show

Reported Side Effects for Linzess 145mcg Capsule

Close Show
Dehydration Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Headache Incidence:
<4.0%*
Severity: MILD
Onset: EARLY
Sinus Infection Incidence:
<3.0%*
Severity: MILD
Onset: DELAYED
Hives Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Intestinal Bleeding Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Infection Incidence:
<5.0%*
Severity: MILD
Onset: DELAYED
Fecal Incontinence Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Melena Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Upset Stomach Incidence:
1.0-1.9%*
Severity: MILD
Onset: EARLY
Tired Incidence:
1.0-1.9%*
Severity: MILD
Onset: EARLY
Vomiting Incidence:
1.0-1.9%*
Severity: MILD
Onset: EARLY
Heartburn Incidence:
1.0-1.9%*
Severity: MILD
Onset: DELAYED
Loose Stools Incidence:
2.0%*
Severity: SEVERE
Onset: EARLY
Gas Incidence:
4.0-6.0%*
Severity: MILD
Onset: EARLY
Stomach Pain Incidence:
7.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
Close Show
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Compatible - This drug is generally safe to take by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Linzess

Close Show

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.